POSTERS & PUBLICATIONS
From the latest randomized trials and methodologies to solid research results, find all the information you need. Click on any media below to download.
Differential efficacy of pegfilgrastim (Peg) in patients (pts) with breast cancer (BC) versus other cancer types for the prevention of docetaxel (Doc) chemotherapy-induced neutropenia (CIN).
Plinabulin and pegfilgrastim versus pegfilgastrim monotherapy after TAC: A comparison of efficacy, safety, relative dose intensity (RDI) and bone pain.
Protective 2 (BPI 2358 106): a Confirmatory Trial to Demonstrate Superiority of the Plinabulin (Plin) + Pegfilgrastim (Peg) Comb ination versus Standard of Care Pegfilgrastim for the Prevention of Chemotherapy Induced Neutropenia in Breast Cancer Patients.
Plinabulin is a more Favorable Option for the Prevention of Chemotherapy Induced Neutropenia (CIN) than Pegfilgrastimduring the COVID-19 Pandemic.
Prediction of Febrile Neutropenia , Hospitalization Rates, and Infection Rates in Chemotherapy-Induced Neutropenia Patients Treated with the Plinabulin and Pegfilgrastim Combination (Plin+Peg) using a Meta-Analysis -based Tool
Adding Plinabulin (Plin) to Pegfilgrastim (Peg) Reverses the Immune Suppressive Potential of Peg while Offering Superior Prevention of Chemotherapy Induced Neutropenia (CIN) versus Peg Alone
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Phase 1 Study of the Novel Vascular Disrupting Agent Plinabulin (NPI-2358) and Docetaxel
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas